Fig. 3From: Long-term safety and efficacy of Omnitrope®, a somatropin biosimilar, in children requiring growth hormone treatment: Italian interim analysis of the PATRO Children studyChange in height velocity standard deviation scores (HVSDS) in the total hormone-naïve patient population and in hormone-naïve patients with growth hormone deficiency (GHD) included in the efficacy analysis set over 5 years. BL, baselineBack to article page